Some images has been designed using resources from Unsplash & Pixabay & Pexels & Freepik and some icons from Flaticon
跳到主要內容
:::
:::

近年臨床試驗

 

 

 

 

 

仍進行中的收案

protocol number

IRB No.

protocol name

sponsor

CRO

PI

承接的SC

PL001-NHL-201

2021-04-007C

Phase 1/2 study of CD19 chimeric antigen
receptor T-cell (CD19 CAR-T) for relapsed or
refractory B-cell lymphoma

Pell Bio-Med

Parexel

蕭樑材

黃淑香

NEOD001-301

2021-12-001A

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis.

Prothena

ICONPRA

劉耀中

黃淑香

C1071007

2022-04-003BU

A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE MINIMAL RESIDUAL DISEASE-POSITIVE AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION

Pfizer

Parexel

劉嘉仁

陳薇光

M22-132

2022-08-002CU

Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin Lymphoma(BR/GemOx)

AbbVie

AbbVie

蔡淳光

陳薇光

CA057-008

 2022-08-018CU

A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing CC-92480 (BMS-986348), Carfilzomib and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM)

BMS

NA

劉嘉仁

陳薇光

2020年以前(已結束)

2016年進行中之臨床試驗

 

 

 

 

 

最後更新:

回到最上